Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of EUR0.27, EUR0.09 better than the analyst estimate of EUR0.18. Revenue for the quarter came in at EUR246.6 million versus the consensus estimate of EUR269.95 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.